Tau-targeted drugs that are currently under development as AD therapies include (i) Hsp90 inhibitors, (ii) inhibitors of Aβ-induced Tau phosphorylation, (iii) Tau aggregation inhibitors, (iv) O-GlcNAcase inhibitors, and (v) GSK-3β inhibitors. Here, MAPT is linked to Alzheimer disease.